Abstract Background
Chronic plaque psoriasis is the most common type of psoriasis and is characterised by redness, thickness and scaling. First line management is with topical treatments.
Objective
Our objective was to establish the effectiveness, tolerability and safety of topical treatments for people with chronic plaque psoriasis of the scalp, assessing placebo-controlled trials of all treatments and head-to-head trials that assessed vitamin D analogues.
Methods
As part of a Cochrane review of topical treatments for psoriasis we systematically searched electronic databases for randomized controlled trials. The review included 26 randomised controlled trials of treatments for psoriasis of the scalp with 8,020 participants. Trials used several measures to assess changes in psoriasis severity: these were combined using the standardised mean difference metric and interpreted by reporting as a 6-point global improvement score.
Results
On effectiveness grounds, very potent or potent steroid treatments should be preferred to vitamin D3 analogue with approximately an average 10% additional improvement on a 6-point scale. Vitamin D3 analogue combined with potent steroid appears more effective than monotherapy with either vitamin D3 or steroids. Rates of withdrawal from treatment and adverse events in trials were generally low and similar to those for placebo. There remains uncertainty about the atrophic potential of corticosteroid treatments for scalp psoriasis.
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Background
Psoriasis is a chronic inflammatory skin disease with a prevalence ranging from 1-2% in the UK and northern European populations 1 2 down to 0.1 to 0.3% in the Far East 3 and China. 4 Chronic plaque psoriasis may be localised or widespread and accounts for 90% of psoriasis cases; 5 it is characterised by red patches of thickened skin (plaques) covered in silver scales. Any area of the body may be affected, but the main areas are the knees, elbows, lower back and scalp. There is a wide spectrum of disease severity from a single plaque to involvement of more than 90% of the skin surface.
Psoriasis can lead to social isolation, 6 stigmatisation 7 and can adversely affect quality of daily life. [8] [9] [10] [11] [12] [13] [14] [15] Psoriasis of the scalp affects up to 79% of people with chronic plaque psoriasis; the scalp is typically the first area of the body to be affected, and the frequency of involvement increases with the duration of the disease. 16 Disease progression is complex and appears to be influenced by many factors including local trauma, infections, certain drugs (such as beta-blockers, lithium, chloroquine and non-steroidal antiinflammatory drugs (NSAIDs)), the duration of antipsoriatic treatments, endocrine factors, sunlight, alcohol, smoking and stress. 17 The skin lesions of psoriasis are characterised by cells multiplying too quickly (epidermal hyperproliferation), cells not maturing normally (abnormal keratinocyte differentiation) and the presence of cells which cause inflammation (a lymphocyte inflammatory infiltrate). [18] [19] [20] Psoriasis is now recognised as an immune-mediated disorder, with tumour necrosis factor alpha (TNFα), dendritic cells and T-cells all contributing to its pathogenesis. 21 A meta-analysis 22 of three genome-wide association studies (GWAS) identified 15 new chromosomal susceptibility loci for psoriasis, bringing the total number of loci known to be associated with psoriasis to 36. Several of these loci are involved in the regulation of the skin's innate immune response. They provide confirmation of the role of several existing biologic therapies and provide new targets for drug development.
Topical treatments are the main therapy for psoriasis of the scalp, whatever the level of disease severity. 16 They include vitamin D analogues, used alone or in combination with potent corticosteroids; potent and very potent corticosteroids; coal tar; and other treatments. 23 24 Scalp psoriasis is one of the most challenging forms of the disease to manage, because the presence of hair makes the use of ointments and cream-based products "difficult and messy". 25 Lotions, shampoos, gels and sprays are all used as vehicles for active treatment.
This paper is based on a Cochrane review 26 27 most recently substantially amended in The Cochrane
Library 2013, Issue (3) (see http://www.thecochranelibrary.com). 28 Cochrane reviews are regularly updated as new evidence emerges and in response to feedback; the Cochrane Library should be consulted for the full and most recent version of the review.
Objective
To compare the effectiveness, tolerability and safety of topical treatments for people with chronic plaque psoriasis of the scalp relative to placebo, and to compare vitamin D analogues head-to-head with other topical treatments.
Methods
This research presents a subset of a larger Cochrane review on topical treatments for chronic plaque psoriasis (Mason 2013, in press ). 28 The full review includes 177 studies, reported in 242 articles. The methods reported here are those used for the full review, including trials of body and scalp psoriasis.
Inclusion criteria
We included only randomised controlled trials in the review. Trials could be either placebocontrolled or have an active comparison with a vitamin D preparation. We selected vitamin D analogues for this comparison because they are first-line treatments in many developed countries. 29 Trials of systemic or ultra-violet (phototherapy) treatments with adjunctive topical treatment were not eligible for inclusion. We excluded the study if no useful effectiveness, withdrawal or adverse 6 events data were available, either from the published paper or from sponsors or trialists, we excluded the study.
Data extraction
One author extracted study data and assessed study quality. A second author checked these data. 
Searches

Outcomes
We extracted data from trials on four primary outcomes ( Table 2 ). Trials often reported more than one measure, but no trial reported all of the measures. We therefore devised a 'combined endpoint' to facilitate treatment comparisons, and use this to report summary findings from the review. We constructed the combined endpoint by taking primary outcomes data in the order listed in Table 2, according to availability. Thus within-trial differences essentially capture a common construct of change in psoriasis severity due to treatment, regardless of the outcome measure used. Additionally we extracted data on five secondary outcomes: data on withdrawal due to any cause, to adverse events and to treatment failure, as well as adverse events due to local and systemic effects.
TABLE 2 HERE
Statistical Methods
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We analysed and pooled findings using a standardised mean difference (SMD) statistic within a random effects model. We report heterogeneity Q (χ 2 ) statistic and I 2 statistics, noting heterogeneity according to the Cochrane Handbook's "rough guide to interpretation": 50% to 90%: may represent substantial heterogeneity and 75% to 100% considerable heterogeneity. 30 Where studies did not report estimates of variance, we derived them from confidence intervals or from P values where possible, or imputed them deterministically by pooling the standard deviations of treatment cohorts fully reported in trials and adjusted for scale. SMD combined endpoints were transformed back to natural units on a 6-point improvement (Investigators Global Assessment of improvement; IAGI) scale (ranging from 'worse' to 'clearance') using pooled IAGI standard deviations. As definitions of withdrawal and adverse events vary between trials, data were summarised using a random effects risk difference metric.
Interpretation
Interpreting the weight of evidence in support of a treatment is ultimately arbitrary, nonetheless there are two accepted principles (all things being equal): first, consistent findings from multiple independent trials provide stronger evidence than one trial alone; and second, trials with larger numbers of patients are preferable to smaller ones because of the lower risk of inferential error.
These two principles are used to interpret available evidence for the clinical management of scalp psoriasis. The statistical significance of findings was determined at the 5% level.
Results
The review included 26 trials of scalp psoriasis: 31-56 14 trials were placebo controlled only; 11 compared vitamin D with other active treatment; and, one additional trial 41 reported both placebocontrolled and active comparisons. Table 3 summarises the characteristics of the scalp trials reviewed.
.
TABLE 3 HERE
Of the 20 trials that reported baseline disease severity, the majority (13/20, 65%) investigated moderate to severe psoriasis of the scalp (Figure 1 ).
FIGURE 1 HERE
Treatment duration averaged 7 weeks, but ranged from 2 weeks to 52 weeks. With the exception of one within-patient (right-left) study that was published in 1978, 47 trials were between-patient (parallel group) in design. demonstrated that groups were comparable in both clinical and demographic characteristics.
Placebo-controlled trials
We found placebo-controlled evidence of effectiveness for 11 treatments for scalp psoriasis ( Figure   3 ). Thirteen between-patient trials and one within-patient trial 47 contributed data from 3011
participants. Patient participation in the trials ranged between two and eight weeks. Two further treatments, each assessed by one small trial, were no more effective than placebo (ciclopirox olamine shampoo, and salicylic acid).
Placebo-controlled trials do not provide adequately precise findings to rank all available treatment options using indirect (placebo-controlled) comparisons. However available evidence suggests a ranking of monotherapies for effectiveness of clobetasol propionate (very potent corticosteroid), betamethasone dipropionate (potent steroid) and then calcipotriol (vitamin-D3 analogue).
Head-to-head trials
Direct (head-to-head) comparisons were made of vitamin D analogues (alone or in combination)
with other treatments (Figure 4 ). Twelve studies contributed data from 5413 patients. Trial durations ranged from 4 to 8 weeks in eleven studies, but the duration was 52 weeks in one trial. 
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Findings were heterogeneous for trials comparing calcipotriol with coal tar polytherapy (3 trials; I 2 = 90%, N=835), ranging from no benefit to 1.2 points on a 6-point global improvement scale.
Withdrawals
For most treatments, rates of total withdrawal, withdrawal due to adverse events, withdrawal due to treatment failure were similar to those for placebo ('placebo-like') and not statistically significantly different; however, evidence for individual treatments was typically informed by individual small trials. When pooled findings from multiple trials were assessed, placebo-like withdrawal was only supported for calcipotriol (3 trials; I 2 =0%; N=517). Overall, evidence on clobetasol propionate suggested the withdrawal rate was similar to placebo but findings were heterogeneous (5 trials; I 2 =89%; N=1006). There was evidence from two trials that withdrawal rates for combined calcipotriol and betamethasone valerate was lower than placebo (RD -9%; 95%CI -16% to -3%; 2 trials; I 2 =0%; N=854).
Withdrawal rates for head-to-head comparisons of treatments consistently suggested slightly lower withdrawal from corticosteroids than from calcipotriol although this finding was not significant at the level of individual treatments. There was some evidence to suggest greater withdrawal with calcipotriol than combined calcipotriol and betamethasone valerate, although findings were heterogeneous (5 trials; I 2 =79%; N=2847), with higher withdrawal for calcipotriol varying from 5% to 18%.
Adverse events
Rates of local adverse events were very low and placebo-like, although only consistently informed by multiple trials and substantial numbers of patients for calcipotriol and clobetasol propionate.
Evidence from head-to-head trials supports the central finding of no important differences between treatments. Calcipotriol monotherapy, when compared with combined calcipotriol and betamethasone, was associated with higher adverse event rates although some of these findings were heterogeneous.
Seven of the 19 trials that included a corticosteroid (alone or in combination) reported that atrophy had been assessed. 33 40 46 50-52 57 Four trials reported no atrophy: treatments tested in these trials included clobetasol propionate shampoo, 40 potent corticosteroids, 50 and combination treatment with calcipotriol and betamethasone dipropionate. 46 48 The remaining three trials reported instances of atrophy, 33 51 52 all investigating clobetasol propionate. The method used to assess atrophy was described in only two trials and was unclear in all other trials. In Luger 2008, 48 a 52 week trial that compared combination therapy with vitamin D monotherapy, an independent adjudication committee decided whether the cases observed by the investigator were likely to be attributable to treatment. Poulin 2010 relied on self-report by study participants.
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Discussion
This review identified 26 trials of scalp psoriasis with 8,020 participants, with most trials investigating moderate to severe disease. Despite a range of topical therapeutic options there is substantial evidence for only a few treatment options: clobetasol propionate, betamethasone dipropionate, betamethasone valerate, calcipotriol and calcipotriol combined with potent steroid.
Other corticosteroids suggest similar performance although findings are imprecise or based on findings of single trials. We did not find evidence to support the first-line use of a tar-based shampoo (with or without a keratolytic, such as salicylic acid, for significant scaling), a current formulary recommendation. 
Conclusions
There is evidence for the effectiveness and tolerability of a range of topical therapeutic options for scalp psoriasis, although this evidence is adequate for a limited number of treatments. On effectiveness grounds, very potent (clobetasol propionate) or potent steroid treatments should be preferred to vitamin D3 analogue (calcipotriol). Calcipotriol combined with potent steroid may be a therapeutic option in cases that do not respond to monotherapy. The atrophic potential of corticosteroid treatments for scalp psoriasis remains unclear, and future studies should report cases of atrophy consistently and using robust assessment methods. 
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